Trials / Unknown
UnknownNCT01023893
Blood Viscosity, End-Stage Renal Disease, And Mortality (BEAM-1)
Clinical Diagnostic Evaluation Study of Blood Viscosity, End-Stage Renal Disease, And Mortality
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 400 (estimated)
- Sponsor
- ProMetrics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Prospective, real-time observational study of hemodialysis patients treated with erythropoiesis-stimulating agents (ESA) to currently recommended Hgb targets. Subjects will be evaluated dynamically for their blood viscosity status at the beginning and end of the dialysis treatment, and followed prospectively to assess outcomes. Blood specimens will be collected via the subject's hemodialysis port pre- and post-hemodialysis per study assessment visit. Blood will be analyzed at a designated laboratory facility for viscosity over a comprehensive range of shear rates and tested for intradialytic surges in blood viscosity. Subjects will be followed for 48 weeks.
Conditions
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2010-11-01
- First posted
- 2009-12-02
- Last updated
- 2009-12-02
Source: ClinicalTrials.gov record NCT01023893. Inclusion in this directory is not an endorsement.